Oncotype DX AR-V7 Test for Prostate Cancer Patients

Share this article

The new Oncotype DX AR-V7 Nucleus Detect Test Determines Benefit of AR-Targeted Therapy in Men with Late-Stage Metastatic Castration-Resistant Prostate Cancer

Patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) have a new tool to help guide their treatment. The new Oncotype DX AR-V7 Nucleus Detect liquid biopsy test identifies whether a patient’s disease will respond to commonly prescribed androgen receptor (AR)-targeted drugs such as XTANDI® or ZYTIGA® , or whether the patient should consider chemotherapy or other therapies.

The Oncotype DX AR-V7 test is a simple blood test that accurately identifies AR-V7 proteins in the nucleus of circulating tumor cells. A positive result means the patient will not respond to AR-targeted therapies and should consider chemotherapy or other treatments. A negative result means the patient may benefit from another AR-therapy.

AR-targeted drugs help slow the growth of prostate cancer. However, over time, these drugs lose their effectiveness in most mCRPC patients, and studies show that patients who are AR-V7 positive are more likely to live longer when treated with chemotherapy versus AR-targeted drugs.

The Oncotype DX AR-V7 test is now available in the U.S., and it is estimated that 50,000 men with mCRPC could benefit from knowing their AR-V7 status prior to selecting further treatment.

1. Xtandi® is a registered trademark of Astellas Pharma, Inc., and Zytiga® is a registered trademark of Johnson and Johnson.
2. Based on studies to date, including Scher et al. JAMA Oncol. 2016 and Scher et al. ASCO GU 2018

Biology Matters
Biology Matters: DOWNLOAD THE INFOGRPAHIC
Oncotype DX My Colon Cancer Coach